Literature DB >> 6854055

Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients.

A J Sober, C L Day, T B Fitzpatrick, R A Lew, A W Kopf, M C Mihm.   

Abstract

We studied 14 prognostic factors in 428 patients with clinical stage I melanoma to determine which factor or combination of factors was associated with death from melanoma from 24 to 60 months following diagnosis. Forty-eight patients (11 percent) died during this period. All 17 patients who had visceral metastases present at 24 months died during this period. All surviving patients were followed for at least 60 months. Individual high risk factors included ulceration width (as determined by histology), level IV or V tumor, recurrence other than visceral, 6 or more mitoses per square millimeter, presence of involved nodes on elective dissection, absent or slight lymphocyte response, tumor type other than superficial spreading, location other than extremities (excluding hands and feet), microscopic satellites, thickness, sex, and wide local excision. The presence of sex as a risk factor for patients dying from 2 to 5 years following diagnosis is noteworthy because no sex difference was noted in the early death (less than 24 months) group. Age, presence of a nevus, and histologic regression were not significant factors. A logistic regression analysis selected a combination of the following independent factors: (1) location on extremities excluding hands and feet (favorable), (2) thickness, (3) recurrence other than visceral, (4) positive elective nodal dissection, (5) 6 or more mitoses per square millimeter, and (6) moderate to marked lymphocyte response (favorable). Twenty-five percent of patients with level IV lesions died between 24 and 60 months compared with only a 6 percent death rate within the first 24 months.

Entities:  

Mesh:

Year:  1983        PMID: 6854055

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

1.  Malignant melanoma--its precursors and its topography of proliferation. DNA-Feulgen-cytophotometry and mitosis index.

Authors:  P Schmiegelow; R Schroiff; E Breitbart; J Bahnsen; J Lindner; M Jänner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

2.  The Ki-67 antigen in primary human melanomas--its relationship to mitotic rate and tumor thickness and its stability.

Authors:  H Ostmeier; L Suter
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

Review 3.  Advances in immunotherapy for melanoma.

Authors:  Jason M Redman; Geoffrey T Gibney; Michael B Atkins
Journal:  BMC Med       Date:  2016-02-06       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.